Matthew Foy
QuietNamed in filings at AmzlOn the current fund
- Board seats filed
- 2
- Named on a board
- 0
all filings on record
Named in filings at AmzlOn the current fund
all filings on record
last 24 months
from a verified or cited source
| FORE US Bio | Biotech & pharma | August 2023 | Orbimed Israel Partners, Synapse Investment |
| Atox Bio | Biotech & pharma | December 2017 | Orbimed Israel Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Too few filings to infer a focus. 2 of 2 filed seats classified so far.